TNBC, Immunotherapy & Clinical Trials: A Survivor’s Story

For Breast Cancer Awareness Month, LaToya Bolds-Johnson’s story offers a window into why clinical trials matter.

Key Takeaways:

  • Triple-negative breast cancer (TNBC) does not have estrogen or progesterone receptors or high levels of HER2, and it often grows and spreads more quickly than other types of breast cancer.
  • Immunotherapy is used for certain people with TNBC, and researchers are studying how to make immune-based treatments work for more people with breast cancer.
  • Clinical trials are not necessarily a last resort. A trial may be worth considering at diagnosis, if cancer returns, or when standard treatments are no longer working.
  • LaToya’s experience led her to immunotherapy, a clinical trial, and a new career as a clinical research sub-investigator.

When LaToya Bolds-Johnson was diagnosed with breast cancer at age 36, she already knew medicine well.

LaToya Bolds Johnson

A physician assistant with years of clinical experience, LaToya was accustomed to being the person caring for patients. Suddenly, she was the patient — a mother of three young daughters facing stage 3 triple-negative breast cancer (TNBC) and trying to understand what came next.

Her experience would eventually lead her to immunotherapy, a clinical trial, and a new chapter of her career in clinical research. But it also reinforced something LaToya now encourages other patients to do: learn about your options, ask questions, and advocate for yourself.

Her story offers a window into why clinical trials matter — not only for advancing breast cancer treatment, but for helping researchers learn which treatments work, for whom, and how cancer care can continue to improve.


Breast cancer is the most commonly diagnosed cancer among women worldwide. According to the American Cancer Society, in the United States, an estimated 321,910 new cases of invasive breast cancer are expected among women in 2026.

But “breast cancer” describes a group of diseases with important biological differences.

Breast cancers are commonly grouped according to proteins found on or inside cancer cells. Hormone receptor-positive cancers have receptors for estrogen, progesterone, or both. HER2-positive cancers have high levels of a protein involved in cell growth called HER2.

Triple-negative breast cancer (TNBC) is a type of breast cancer that does not have estrogen or progesterone receptors and does not have high levels of HER2. It is the type LaToya was diagnosed with. TNBC often grows and spreads more quickly than many other types of breast cancer.

Those differences matter because they help determine which treatments may work. Biomarker and genetic testing can provide additional information about a tumor and help patients and their health care teams understand available treatment options, including whether immunotherapy may be appropriate.

Today, immunotherapy is used for certain people with TNBC. Researchers are also studying how to make immune-based treatments effective for more people with breast cancer.

And much of that progress happens through clinical trials.

Clinical trials are carefully monitored research studies that evaluate new treatments or new ways of using existing treatments.

For patients, trials may provide access to promising approaches that are not yet widely available. For researchers, they answer the questions necessary to move cancer treatment forward: Is a treatment safe? Does it work? Which patients are most likely to benefit? Could two treatments work better together?

Importantly, clinical trials are not necessarily a last resort.

Depending on a person’s diagnosis and individual circumstances, a trial may be worth considering at different points in care — including at diagnosis, if cancer returns, or when standard treatments are no longer working.

Researchers are currently evaluating several immune-based approaches for breast cancer, including new uses and combinations of checkpoint inhibitors, therapeutic cancer vaccines, cell and gene therapies, immune cell engagers, and combinations of immunotherapy with treatments such as chemotherapy, targeted therapies, radiation, and antibody-drug conjugates.

For LaToya, participating in a clinical trial became about something even bigger than her own treatment.


LaToya is a mother to three daughters. When she thought about participating in research, she also thought about them.

“My whole mission with being the clinical trial participant is that I wanted to make sure that I was building a medical trust fund for my children,” she said.

Just as a parent might build an educational or financial fund for a child’s future, LaToya saw contributing to medical research as another kind of investment.

She wanted her participation to add information researchers could learn from — information that might someday help her daughters, future generations of her family, and other people who share aspects of her biological background.

Magenta quote mark

I just wanted to make my mark on that, to move the needle forward in science so that we can get the latest and greatest treatment options for someone with my biological profile.

That participation matters. Clinical research needs people from different racial and ethnic backgrounds, ages, and communities so researchers can better understand how treatments affect the people who may ultimately receive them.

For LaToya, that issue became part of her advocacy after cancer as well.


LaToya was diagnosed in July 2021.

She has been off treatment, including immunotherapy, since April 2023. But she is also quick to point out that finishing treatment does not mean the experience of cancer simply disappears.

“The cancer journey never ends,” she said. There can still be fear of recurrence, along with the physical, mental, and emotional effects that remain after treatment.

Those experiences have shaped what came next.

LaToya has become involved in breast cancer advocacy, including efforts focused on clinical trial equity and the mental health of survivors. She is returning to the doctoral studies she put on hold after her diagnosis. And she has found another way to share her family’s experience: through a children’s book, When Life Gives You Lemons, Make Pink Lemonade. Told through the eyes of her daughter, the story follows three sisters as they turn their summer lemonade stand into a mission of hope after their mother’s breast cancer diagnosis.

Her professional life has taken an unexpected turn, too: the physician assistant who became a patient and clinical trial participant now works as a clinical research sub-investigator.

For her, it feels remarkably full circle.

She is once again working with patients — this time from the research side of medicine and in a field she came to understand in an intensely personal way.

A clinical trial will not be the right choice for every person with breast cancer. Neither will immunotherapy.

But patients deserve the opportunity to understand the options that may be available to them.

That can begin with a conversation with your health care team.

Questions to Ask Your Health Care Team

  • What type of breast cancer do I have?
  • What biomarkers have been tested?
  • Is immunotherapy an option for me?
  • Are there clinical trials I should consider now — or might there be trials to consider later?

For LaToya, asking questions and advocating for herself became part of navigating cancer. Today, the knowledge generated through clinical research is something she hopes will help make those conversations — and the options available to patients — better for generations to come.


Clinical Trial FAQs

Are clinical trials safe?

All clinical trials must follow strict rules set by the FDA and an Institutional Review Board (IRB) to protect participants. Your safety is monitored at every step, and you can choose to stop participating at any time.

Will I know what treatment I’m getting? What if I get the placebo?

In some clinical trials, you will know what treatment you will receive. In others, treatments are “blinded” to prevent study bias. Placebos are rarely used in cancer treatment trials and never given alone. Participants usually receive the study treatment or the current standard of care.

Can I join more than one trial?

Usually, patients can only participate in one clinical trial at a time, but you may be eligible for another trial after the first one ends. If you are eligible for more than one trial at any time, CRI’s Clinical Trial Navigators can help you determine which one might be right for you.

Will joining a clinical trial delay or change my treatment?

Joining a clinical trial usually does not delay treatment; you may even get treatment sooner. Many trials start quickly once you’re screened and enrolled.

How much extra time will a clinical trial take?

Some clinical trials require more visits and tests than standard care. Ask the clinical trial team about the time commitment before joining to see if it’s right for you.

Where do trials take place, and can I keep my doctor?

Many clinical trials take place at major cancer centers across the U.S., but some are in community hospitals or local clinics. Your doctor usually remains an important part of your health care team and can stay involved throughout the process.

What about side effects?

Before you join the clinical trial, you’ll learn about potential risks such as side effects. Once enrolled, the clinical trial team will monitor you closely and help manage any side effects. Learn about common immunotherapy side effects.

Are there clinical trials for children, teens, or young adults with cancer?

Yes. Some clinical trials are designed specifically for pediatric or young adult patients. CRI’s Clinical Trial Navigators can help you identify these.

What happens to my data and samples after the trial?

Some clinical trials ask permission to store your data and samples for future cancer research. You can decide whether to give consent to this or not.

Are clinical trials for people like me?

Yes. Clinical trials rely on participants from all backgrounds – different ages, races, ethnicities, and communities – to ensure treatments work and are accessible for everyone.

Does CRI run clinical trials?

No, CRI does not run clinical trials, but CRI supports early-phase immunotherapy clinical trials through our Clinical Innovator Award. Read about ongoing trials for pancreatic cancer, bladder cancer, oral lesions, and more.

How can I stay updated on the latest immunotherapy research and treatments?

CRI regularly publishes educational resources and newsletters designed for patients, families, and caregivers. Sign up to receive updates on research and treatment advances. Explore CRI-funded research projects now.

Graphic illustration of a map

CRI’s Clinical Trial Finder can help patients and caregivers search for immunotherapy clinical trials and connect with clinical trial navigation resources.


Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

Father and son